EGFR and breast cancer: Other aptamers that can specifically bind to EGFRVIII, a frequently identified mutant form of EGFR in breast cancer, lung cancer and glioblastoma, were shown to possess great potential as molecular anti-tumor reagents in cancers carrying the EGFRVIII mutation especially glioblastoma [32-34].